Read Gene Spolka Akcyjna Logo

Read Gene Spolka Akcyjna

RDG | WAR

Overview

Corporate Details

ISIN(s):
PLRADGN00014 (+1 more)
LEI:
2594003D7O7NDUV8GE29
Country:
Poland
Address:
Dobra Grzepnica-Alabastrowa 8, 72-003 Dobra
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Read-Gene S.A. is an innovative biotechnology company focused on the commercialization of methods for the detection, prevention, and treatment of malignant tumors. Established in 2005, the company's core operations are centered on three complementary segments: genetic testing, chemoprevention, and clinical trials. It develops and provides advanced DNA tests that identify genetic predispositions to cancer, enabling precise prophylaxis and facilitating earlier treatment. Additionally, the company offers advisory and support services for oncological genetic counseling centers. Read-Gene is distinguished by its strong scientific foundation, with a team of renowned scientists from the International Hereditary Cancer Center, and holds numerous patents for its novel cancer risk assessment technologies.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Read Gene Spolka Akcyjna. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2024-03-25 10:54
Regulatory News Service
Decyzja o ochronie patentowej na wynalazek - Content (PL)
Polish 1.0 KB
2024-03-25 10:51
Regulatory News Service
Decyzja o ochronie patentowej na wynalazek - Content (PL)
Polish 1.1 KB
2023-11-22 16:45
Regulatory News Service
Decyzja o ochronie patentowej na wynalazek - Content (PL)
Polish 1.2 KB
2023-11-16 17:31
Legal Proceedings Report
Decyzja o ochronie patentowej na wynalazek - Content (PL)
Polish 1.2 KB
2023-10-26 16:35
Legal Proceedings Report
Decyzja o ochronie patentowej na wynalazek - Content (PL)
Polish 1.2 KB
2023-08-07 12:11
Regulatory News Service
Decyzja o ochronie patentowej na wynalazek - Content (PL)
Polish 1.4 KB
2023-08-07 12:08
Regulatory News Service
Decyzja o ochronie patentowej na wynalazek - Content (PL)
Polish 1.8 KB
2023-08-07 12:04
Registration Form
Decyzja o ochronie patentowej na wynalazek - Content (PL)
Polish 1.2 KB
2023-08-07 12:01
Regulatory News Service
Decyzja o ochronie patentowej na wynalazek - Content (PL)
Polish 1.2 KB
2023-08-02 13:48
Regulatory News Service
Decyzja o ochronie patentowej na wynalazek - Content (PL)
Polish 1.1 KB
2023-08-02 13:45
Legal Proceedings Report
Decyzja o ochronie patentowej na wynalazek - Content (PL)
Polish 1.2 KB
2023-08-01 15:06
Regulatory News Service
Decyzja o ochronie patentowej na wynalazek - Content (PL)
Polish 1.2 KB
2023-08-01 15:04
Regulatory News Service
Decyzja o ochronie patentowej na wynalazek - Content (PL)
Polish 1.2 KB
2023-06-30 17:30
Declaration of Voting Results & Voting Rights Announcements
Wykaz akcjonariuszy posiadających co najmniej 5% głosów na ZWZ READ-GENE S.A. w…
Polish 584 bytes
2023-06-29 13:27
Director's Dealing
powiadomienie_o_transakcjach_-_zmiana.pdf
Polish 11.9 KB

Automate Your Workflow. Get a real-time feed of all Read Gene Spolka Akcyjna filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Read Gene Spolka Akcyjna via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
1NKEMIA Logo
Offers contract R&D, develops tech platforms, and invests in life sciences ventures.
Spain IKM
2cureX AB Logo
Tests cancer drugs on patient-derived micro-tumors for personalized oncology treatments.
Sweden 2CUREX
4SC AG Logo
Developing epigenetic small-molecule drugs for cancers with high unmet medical needs.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using an OMV platform for major infectious diseases.
Sweden ABERA
ABIVAX Logo
Developing oral drugs for chronic inflammatory diseases like ulcerative colitis and Crohn's disease.
France ABVX
Abliva Logo
A clinical-stage biotech developing medicines for rare primary mitochondrial diseases.
Sweden ABLI
Achiko AG Logo
A liquidated health tech firm that developed aptamer diagnostics and a COVID-19 passport app.
Switzerland ACHI
Acticor Biotech Logo
Biopharma developing first-in-class drugs for acute stroke and other thrombotic diseases.
France ALACT
Active Biotech Logo
Develops immunotherapies for cancer and inflammatory diseases with significant unmet needs.
Sweden ACTI
Addex Therapeutics Ltd Logo
Develops oral small molecule drugs, allosteric modulators, for neurological disorders.
Switzerland ADXN